Loxo Oncology

Showing 3 posts of 3 posts found.


Eli Lilly to buy Loxo Oncology in deal worth $8 billion

January 7, 2019
Manufacturing and Production Cancer, Eli Lilly, Loxo Oncology, gene therapy, personalised medicine

US firm Eli Lilly & Co today announced a definitive agreement for the acquisition of Connecticut-based company Loxo Oncology in …


FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi

November 27, 2018
Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma

The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …


New targeted therapy promises strong response rate across 17 cancer types

June 5, 2017
Research and Development, Sales and Marketing ASCO, Cancer, Loxo Oncology, oncology

Loxo Oncology’s lead therapy larotrectinib made a big impact at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, …

Latest content